Atlas Trials

Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

Clinical trial NCT02712320 · COMPLETED

Trial details

NCT number
NCT02712320
Sponsor
Foresee Pharmaceuticals Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Prostatic Neoplasms
Start date
2016-02-01
Primary completion
2017-05-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.